Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 3/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | ACVR2A | P27037 | 3/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867009 | 0.92 | NLRP3 (0.36) | NLRP3CYP46A1PLCG1EGLN1 | |
| SCHEMBL22866621 | 0.80 | CYP46A1 (0.40) | NLRP3CYP46A1NR4A2DHODHPDE3B | |
| SCHEMBL25281510 | 0.80 | CNR1 (0.43) | NLRP3CYP46A1NR4A2DHODHPDE3B | |
| SCHEMBL22867010 | 0.80 | ACVR2A (0.39) | NLRP3PLCG1PDE3BPDE3APTGDR2 | |
| SCHEMBL22867183 | 0.78 | NLRP3 (0.37) | NLRP3PDE3BPDE3AACVR2ATGFBR1 | |
| SCHEMBL22717203 | 0.71 | CYP46A1 (0.44) | CYP46A1NR4A2DHODHPDE3BPDE3A | |
| SCHEMBL22866864 | 0.71 | PTGDR2 (0.45) | NLRP3NR4A2DHODHPDE3BPDE3A | |
| SCHEMBL22717172 | 0.70 | NR4A2 (0.40) | NLRP3CYP46A1NR4A2DHODHPDE3B | |
| SCHEMBL22774290 | 0.70 | NLRP3 (0.58) | NLRP3NR4A2DHODHPTGDR2ACVR2A | |
| SCHEMBL29691524 | 0.70 | NLRP3 (0.58) | NLRP3NR4A2DHODHPTGDR2ACVR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002274-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | NLRP3 1/4885CYP46A1 352/4885PLCG1 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.